Published in Nanomedicine (Lond) on July 01, 2012
Glaucoma management: relative value and place in therapy of available drug treatments. Ther Adv Chronic Dis (2014) 0.87
The intricacies of neurotrophic factor therapy for retinal ganglion cell rescue in glaucoma: a case for gene therapy. Neural Regen Res (2016) 0.75
Synaptic Dysfunction in Alzheimer's Disease and Glaucoma: From Common Degenerative Mechanisms Toward Neuroprotection. Front Cell Neurosci (2017) 0.75
Glaucoma -state of the art and perspectives on treatment. Restor Neurol Neurosci (2015) 0.75
Discovery and characterization of the laulimalide-microtubule binding mode by mass shift perturbation mapping. Chem Biol (2010) 1.37
Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine (2002) 1.34
Non-viral nucleic acid delivery: key challenges and future directions. Curr Drug Deliv (2011) 1.25
Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J Biotechnol (2004) 1.16
Needle-free topical electroporation improves gene expression from plasmids administered in porcine skin. Mol Ther (2003) 0.97
Topical non-invasive gene delivery using gemini nanoparticles in interferon-gamma-deficient mice. Eur J Pharm Biopharm (2007) 0.89
How do calcium ions induce free radical oxidation of hydroxy-1,4-naphthoquinone? Ca2+ stabilizes the naphthosemiquinone anion-radical of echinochrome A. Arch Biochem Biophys (2003) 0.88
In vivo cutaneous interferon-gamma gene delivery using novel dicationic (gemini) surfactant-plasmid complexes. J Gene Med (2005) 0.88
Identification and characterization of an intermediate taxol binding site within microtubule nanopores and a mechanism for tubulin isotype binding selectivity. J Chem Inf Model (2009) 0.88
Conformational analysis of the carboxy-terminal tails of human beta-tubulin isotypes. Biophys J (2007) 0.88
Advancing nonviral gene delivery: lipid- and surfactant-based nanoparticle design strategies. Nanomedicine (Lond) (2010) 0.87
Identification of tubulin drug binding sites and prediction of relative differences in binding affinities to tubulin isotypes using digital signal processing. J Mol Graph Model (2008) 0.86
Echinochrome, a naturally occurring iron chelator and free radical scavenger in artificial and natural membrane systems. Life Sci (2005) 0.86
Topical delivery of plasmid DNA using biphasic lipid vesicles (Biphasix). J Pharm Pharmacol (2002) 0.86
Homology modeling of tubulin: influence predictions for microtubule's biophysical properties. Eur Biophys J (2006) 0.85
Thermodynamic and aggregation properties of aza- and imino-substituted gemini surfactants designed for gene delivery. Phys Chem Chem Phys (2006) 0.85
Gemini surfactants: a new family of building blocks for non-viral gene delivery systems. Curr Gene Ther (2008) 0.83
Enhanced gene expression in epithelial cells transfected with amino acid-substituted gemini nanoparticles. Eur J Pharm Biopharm (2010) 0.82
Structural and transfection properties of amine-substituted gemini surfactant-based nanoparticles. J Gene Med (2007) 0.82
Transdermal delivery of insulin from a novel biphasic lipid system in diabetic rats. Diabetes Technol Ther (2002) 0.82
Amino acid-substituted gemini surfactant-based nanoparticles as safe and versatile gene delivery agents. Curr Drug Deliv (2011) 0.82
Effect of group II metal cations on catecholate oxidation. Chemphyschem (2007) 0.81
Pharmaceutical characterization of solid and dispersed carbon nanotubes as nanoexcipients. Int J Nanomedicine (2012) 0.81
The haemopoietic growth factor, Flt3L, alters the immune response induced by transcutaneous immunization. Immunology (2002) 0.80
A CD study of uncoupling protein-1 and its transmembrane and matrix-loop domains. Biochem J (2008) 0.80
Investigation of complexes formed by interaction of cationic gemini surfactants with deoxyribonucleic acid. Phys Chem Chem Phys (2007) 0.80
Effect of chemical permeation enhancers on stratum corneum barrier lipid organizational structure and interferon alpha permeability. Mol Pharm (2013) 0.79
Mucosal delivery of bacterial antigens and CpG oligonucleotides formulated in biphasic lipid vesicles in pigs. AAPS J (2005) 0.79
Iron chelators and free radical scavengers in naturally occurring polyhydroxylated 1,4-naphthoquinones. Hemoglobin (2008) 0.79
Microtubule assembly of isotypically purified tubulin and its mixtures. Biophys J (2008) 0.79
Free energy calculations on the binding of colchicine and its derivatives with the alpha/beta-tubulin isoforms. J Chem Inf Model (2008) 0.78
Biphasic lipid vesicles (Biphasix) enhance the adjuvanticity of CpG oligonucleotides following systemic and mucosal administration. Curr Drug Deliv (2004) 0.78
Non-invasive immunization on the skin using DNA vaccine. Curr Drug Deliv (2006) 0.78
Synthesis, characterization, and use of asymmetric pyrenyl-gemini surfactants as emissive components in DNA-lipoplex systems. Langmuir (2007) 0.77
New technology and clinical applications of nanomedicine: highlights of the second annual meeting of the American Academy of Nanomedicine (Part I). Nanomedicine (2006) 0.77
Drug delivery through the skin: molecular simulations of barrier lipids to design more effective noninvasive dermal and transdermal delivery systems for small molecules, biologics, and cosmetics. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 0.76
Protection of Neonatal Broiler Chickens Following in ovo Delivery of Oligodeoxynucleotides Containing CpG Motifs (CpG-ODN) Formulated with Carbon Nanotubes or Liposomes. Avian Dis (2015) 0.76
Enhancement of immunoprotective effect of CpG-ODN by formulation with polyphosphazenes against E. coli septicemia in neonatal chickens. Curr Drug Deliv (2009) 0.76
In vivo sustained dermal delivery and pharmacokinetics of interferon alpha in biphasic vesicles after topical application. Eur J Pharm Biopharm (2013) 0.75
A quantitative evaluation of redox-active compounds in human blood lipids. Hemoglobin (2011) 0.75
Synthesis and solution properties of gemini surfactants containing oleyl chains. Phys Chem Chem Phys (2005) 0.75
A computational model for overcoming drug resistance using selective dual-inhibitors for aurora kinase A and its T217D variant. Mol Pharm (2013) 0.75
Conformational analysis and folding of transmembrane and matrix peptide segments of the mitochondrial uncoupling proteins: a comparative study. Adv Exp Med Biol (2009) 0.75
Evidence for lymphatic transport of insulin by topically applied biphasic vesicles. J Pharm Pharmacol (2003) 0.75
Biphasic lipid vesicles as a subcutaneous delivery system for protein antigens and CpG oligonucleotides. Curr Drug Deliv (2006) 0.75
Nanotechnology enables superior medical therapies. Curr Drug Deliv (2011) 0.75
The 4th Annual Meeting of the American Society for Nanomedicine. J Neuroimmune Pharmacol (2014) 0.75